|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 3 A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in participants with suspected recurrent prostate cancer after radical treatment.
/ Not yet recruitingPhase 3 A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
100 Clinical Results associated with Yunhe Pharmaceutical (Zhejiang) Co., Ltd.
0 Patents (Medical) associated with Yunhe Pharmaceutical (Zhejiang) Co., Ltd.
100 Deals associated with Yunhe Pharmaceutical (Zhejiang) Co., Ltd.
100 Translational Medicine associated with Yunhe Pharmaceutical (Zhejiang) Co., Ltd.